303 related articles for article (PubMed ID: 19542525)
1. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
3. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
Kinon BJ; Lipkovich I; Edwards SB; Adams DH; Ascher-Svanum H; Siris SG
J Clin Psychopharmacol; 2006 Apr; 26(2):157-62. PubMed ID: 16633144
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
6. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
[TBL] [Abstract][Full Text] [Related]
8. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Karayal ON; Glue P; Bachinsky M; Stewart M; Chappell P; Kolluri S; Cavus I
J Psychiatr Pract; 2011 Mar; 17(2):100-9. PubMed ID: 21430488
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
Li YM; Zhao JP; Ou JJ; Wu RR
Pharmacopsychiatry; 2012 Jul; 45(5):177-81. PubMed ID: 22290206
[TBL] [Abstract][Full Text] [Related]
12. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
Kudla D; Lambert M; Domin S; Kasper S; Naber D
Eur Psychiatry; 2007 Apr; 22(3):195-202. PubMed ID: 17140769
[TBL] [Abstract][Full Text] [Related]
14. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
Ou JJ; Xu Y; Chen HH; Fan X; Gao K; Wang J; Guo XF; Wu RR; Zhao JP
Psychopharmacology (Berl); 2013 Feb; 225(3):627-35. PubMed ID: 22926006
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; Bhoopathi PS; Kissling W; Leucht S
Cochrane Database Syst Rev; 2009 Oct; (4):CD006627. PubMed ID: 19821380
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
[TBL] [Abstract][Full Text] [Related]
17. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Potkin SG; Ogasa M; Cucchiaro J; Loebel A
Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
19. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
Wu XL; Wang JH; Hu SH; Tao J
East Asian Arch Psychiatry; 2012 Mar; 22(1):7-11. PubMed ID: 22447799
[TBL] [Abstract][Full Text] [Related]
20. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
